News | January 03, 2024
Glenmark to launch biosimilar of anti-diabetic drug Liraglutide in India
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Liraglutide belongs to the class of glucagon like peptide 1 receptor agonist (GLP?1 RA) drugs
Ribo's cutting edge RIBO-GalSTAR platform enables the development of RNAi therapeutics targeting disease-causing genes specifically in hepatocytes
The survey data presented in “The State of the Biopharmaceutical Industry 2024” report reveals that N=21 (18%) of industry professionals were convinced that CGT will dominate as the most important trend in pharma next year
AMI to become part of Enpro’s Sealing Technologies Segment
The company has received marketing authorisation for docetaxel from Israel and cytarabine from Colombia
Transaction delivers KarXT, a first-in-class M1/ M4 muscarinic receptor agonist with differentiated efficacy and safety
Ami Organics will also sign an MoU with Government of Gujarat for investment amounting up to Rs 300 crores for set up of dedicated manufacturing facility for electrolytes business
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
New facility is part of Aptar Pharma’s global expansion program
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Subscribe To Our Newsletter & Stay Updated
